Identifying the critical factors for commercial-scale viral vector process development and manufacturing

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Identifying the critical factors for commercial-scale viral vector process development and manufacturing

As the cell and gene therapy industry continues to develop at a rapid pace, the ability to manufacture clinical grade viral vectors at a commercial scale is now more crucial than ever before. But how do you decide which vector is most suited to your particular needs, and how should you best approach process development and manufacture to achieve optimal outcomes?

In this free webinar, Behnam Ahmadian Baghbaderani (Global Head of Process Development, Lonza), Xin Swanson (Head of Viral Vector Commercial Development, Lonza) and Suparna Sanyal (Innovation & Commercial Integration Manager, Lonza), will discuss:

Understanding the different types of viral vectors, their profiles and how to select the best vector for your gene of interest
Find out how the industry is currently addressing issues with production volumes and titers, and the implications as more therapies move to commercial scale manufacturing
Viral vector process development potential pitfalls and best practices
Optimising partnerships to de-risk your viral vector manufacturing

The Lonza logo is a Lonza Ltd. Trademark

Behnam Ahmadian Baghbaderani

Lonza Pharma & Biotech

Dr. Baghbaderani is the Global Head of Process Development, Cell and Gene Technologies at Lonza. He has over 15 years of experience in stem cells engineering, bioprocessing, and cell and gene therapy (C&GT) field. Dr. Baghbaderani holds a PhD degree in Biomedical Engineering from the University of Calgary (Calgary, Canada), where he developed bioreactor protocols for large-scale expansion of human neural stem cells for clinical applications.

He completed nearly three years of post-doctoral program including a two-year post-doctoral fellowship at the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS). His post-doctoral research at the NIH focused on generation of human induced pluripotent stem cells, bioprocessing of both human embryonic stem cells and human iPSCs and controlled differentiation into neuronal lineage.

Since joining Lonza in 2011, he led a group of scientists at Lonza process development team, establishing pluripotent stem cells platform technologies and a cGMP compliant manufacturing process for human induced pluripotent stem cells. Dr. Baghbaderani then led the cell therapy development department (including process development and bioassay services), focusing on the development of cGMP compliant processes and cell characterization assays for different cell therapy applications. As the global head of process development, Dr. Baghbaderani is currently leading the development activities for viral vector and C&GT applications across Lonza Cell and Gene Technologies global network.

Xin Swanson

Head, Business Development, Viral-based Therapeutics at Lonza Pharma & Biotech

Xin Swanson serves as the Commercial Development Lead for Lonza’s Viral Vector Gene Therapy Business. She has over 20 years of ex-perience in the Pharma/Biotech industry, developing viral gene therapies and monoclonal antibody therapeutics. Over the course of her career, Xin has held various positions in R&D, Process Development and Commercial Development functions. She has been with Lonza for more than 10 years and has played an instrumental role in the growth of Cell and Gene Therapy business. Xin holds a PhD in Biochemistry from Texas A&M University and an MBA degree.

Suparna Sanyal

CD at Lonza

Suparna Sanyal is an Innovation and Commercialization Manager at Lonza Cell and Gene Technologies where she works with their global business, R&D and operations teams to enable prioritization, strategic development and commercialization of their innovation portfolio. Suparna’s background is in Neuroscience and she earned her PhD from the University of Toronto in Neuropharmacology. She has over 15 years of broad pharmaceutical and CDMO experience driving innovation, drug discovery, product and service development for CNS, oncology and cell and gene therapy.